Navigation Links
ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
Date:8/5/2010

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ... developing new, patent-pending technologies poised to redefine how consumers receive ... hold a business update teleconference and webcast for shareholders and ... at 4:30 PM ET. Fuse Science, Inc. ... call and will be joined by Rubin Hanan ...
(Date:5/17/2013)... 17, 2013  Atossa Genetics, Inc. (NASDAQ: ATOS ... Kyle Guse , Chief Financial Officer & General Counsel, ... on Thursday, May 30, 2013, in New York ... The Company,s presentation is scheduled to begin at 3:30 ... To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013.  ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
... Lions Eye Institute for Transplant and Research, Inc. ... 12,000-square-foot facility in Tampa, Florida. This state-of-the-art facility ... research, study, collaboration, and clinical advancements, as well ... and meetings/events.This marks an expansion of the current ...
... announced its readiness to assist organizations in assembling, communicating, ... phase 5 classification of the Influenza A crisis. ... strong signal that a pandemic is imminent and that ... http://www.newscom.com/cgi-bin/prnh/20080701/DC26612LOGO )A world leader ...
Cached Medicine Technology:Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases 2Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases 3EPSScentral Responds to Pandemic Alert 2
(Date:5/19/2013)... (PRWEB) May 19, 2013 People in Minnesota ... summer. Altman Fitness is offering its 28 Day Fat Loss ... program from the comfort of their own home. The product ... purchase. More information can be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ ... to leave their houses now, but after using the 28 ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Actos ... federal litigation now underway in U.S. District Court, Western ... Order dated May 3rd, the Court has modified the ... to eight cases rather than four. The next Status ... Thursday, May 23rd. (In re: Actos Product Liability Litigation, ...
(Date:5/19/2013)... Today, Zane Benefits, Inc. published ... insurance . Zane Benefits, which provides comprehensive and ... is the leader in health care reform, ... . , According to Zane Benefits’ website, many ... the value of small business health insurance for ...
(Date:5/19/2013)... According to a new market research report "Image ... By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), Surveillance, Automobile, ... Infrared, X-Ray) And Geography" published by MarketsandMarkets, the ... in 2012 and is expected to reach $10.75 ... 3.84% from 2013 to 2018. In terms of ...
(Date:5/19/2013)... May 19, 2013 These molecular ... US, UK, Spain, Japan, Italy, Germany and France:, ... molecular diagnostics laboratory practice, as well as key ... significant market impact during the next five years. ... and biochip technologies, test formats, detection methodologies, trends ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
... at 4:30 p.m. Eastern Time Today -, IRVINE, ... the worldwide leader in intravascular patient temperature,management therapies, today ... fourth quarter and year ended December 31, 2007., ... record $2.7 million,compared to $2.0 million in the fourth ...
... stories of QUITPLAN Services users on display, MINNEAPOLIS, ... efforts of Minnesotans who used the free, professional,counseling from ... photo exhibits in the State Capitol. The exhibits are ... in the North Corridor of State,Capitol near the Rotunda., ...
... than teens, a new study finds, , , THURSDAY, March ... cardiovascular damage in children, especially the very youngest, new ... from 2 to 14 years old, showed that environmental ... and signs of vascular injury, suggesting an increased risk ...
... ALBANY, N.Y., March 13 The following is a,statement ... The Executive Budget proposed including a $400 million Housing,Opportunity ... statewide. These funds will be used to provide needed ... need of supportive,services., The program will be administered ...
... MATK ) announced today that life,sDHA(TM), its ... and heart health, is available in the,new Berri ... from,National Foods, Australia,s No. 1 juice company. National ... Australia, packaging approximately 50,percent of all fruit juice ...
... Blue Shield Members, PITTSBURGH, March 13 ... has received a Brand Excellence Award from the ... awards honor Blue,Cross and Blue Shield companies that ... and Blue Shield Brand image., "BCBSA congratulates ...
Cached Medicine News:Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 2Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 3Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 4Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 5Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 6Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 7Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 8Health News:ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol 2Health News:ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol 3Health News:Secondhand Smoke Hikes Tots' Risk of Heart Disease 2Health News:Secondhand Smoke Hikes Tots' Risk of Heart Disease 3Health News:Australia's Leading Juice Company Launches Juice Blend with Martek's life'sDHA(TM) 2Health News:Australia's Leading Juice Company Launches Juice Blend with Martek's life'sDHA(TM) 3Health News:Highmark Receives Prestigious Brand Excellence Award 2
... AXIOM Artis BC is ... flexible system architecture ideal for ... flexible and ergonomic architecture enables ... system configuration to focus on:, ...
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
... with Tim™ (Total imaging matrix) technology ... and highest resolution at 3T. With ... advanced applications can now be translated ... with Tim is an excellent dual-purpose ...
Medicine Products: